|
|
|
|
|
非在研适应症- |
最高研发阶段临床申请批准 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
|
|
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of ACE-86225106 as Monotherapy in Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
100 项与 Acerand Therapeutics (USA) Ltd. 相关的临床结果
0 项与 Acerand Therapeutics (USA) Ltd. 相关的专利(医药)
100 项与 Acerand Therapeutics (USA) Ltd. 相关的药物交易
100 项与 Acerand Therapeutics (USA) Ltd. 相关的转化医学